-
公开(公告)号:ES2182104T3
公开(公告)日:2003-03-01
申请号:ES97932321
申请日:1997-07-08
Applicant: SCHERING CORP
Inventor: ASBEROM THEODROS , LOWE DEREK B , GREEN MICHAEL J
IPC: A61K31/00 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/4465 , A61K31/4468 , A61K31/4545 , A61K45/06 , A61P25/28 , C07D211/58 , C07D405/12 , C07D405/14 , C07D409/14
Abstract: 1,4-Di-substituted piperidine muscarinic antagonists of formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein X is a bond, -O-, -S-, -SO-, -SO2-, -CO-, -C(OR )2-, -CH2-O-, -O-CH2-, -CH=CH-, -CH2-, -CH(C1-C6 alkyl)-, -C(C1-C6 alkyl)2-, -CONR -, -NR CO-, -SO2NR - or -NR SO2-; R is C3-C6 cycloalkyl, (a), (b), (c), (d), (e), optionally substituted phenyl or optionally substituted pyridyl; R is H, -CN, -CF3, alkyl, cycloalkyl, cycloalkenyl, alkenyl, -COR , -COO(alkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl), alkylaryl, alkylheteroaryl or -CON(R )2; R is cycloalkyl, cycloalkenyl, t-butoxycarbonyl or optionally substituted 4-piperidinyl; R and R are H, halo, -CF3, alkyl, alkoxy or -OH; R and R are H, alkyl, -CF3, alkoxy, -OH, alkylcarbonyl, alkoxycarbonyl, R CONH-, R OCONH-, R NHCONH- or NH2CONR -; R is H or alkyl, or the two R groups may form -(CH2)2-4; R is H, alkyl, cycloalkyl, -(alkyl)COOR , aryl, heteroaryl, alkylaryl, alkylheteroaryl and adamantyl; R is H or alkyl; R is H, C1-C20 alkyl, C1-C6 cycloalkyl, aryl or heteroaryl; and R is H, C1-C6 alkyl, aryl or heteroaryl; useful for treating cognitive disorders such as Alzheimer's disease are disclosed, as well as pharmaceutical compositions and methods of preparation. Also disclosed are combinations of compounds of formula (I) capable of enhancing ACh release with ACh'ase inhibitors.
-
公开(公告)号:CA2455863A1
公开(公告)日:2003-02-20
申请号:CA2455863
申请日:2002-08-01
Applicant: SCHERING CORP
Inventor: ASBEROM THEODROS , PISSARNITSKI DMITRI A , GUZIK HENRY S , JOSIEN HUBERT B
IPC: A61K31/437 , A61K31/47 , A61K31/4709 , A61K31/496 , A61K31/5377 , A61P9/10 , A61P25/00 , A61P25/28 , A61P43/00 , C07D215/58 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D471/04 , C07D487/04 , C07D487/08 , C07D521/00 , C07D401/14 , C07D405/14 , A61K31/475
Abstract: This invention discloses novel gamma secretase inhibitors of the formula:(Chemical formula should be inserted here as it appears on abstract in paper form)wherein: R1 is a substituted aryl or substituted heteroaryl group ; R2 is an R1 group, alkyl, -X(CO)Y, -(CR32)1-4X(CO)Y; each R3A is independent ly H or alkyl; X is -O-, -NH, or -N-alkyl; and Y is -NR6R7, or -N(R3)(CH2)2- 6NR6R7. Also disclosed is a method of treating Alzheimer s Disease.
-
公开(公告)号:HU0100607A2
公开(公告)日:2002-05-29
申请号:HU0100607
申请日:1998-11-23
Applicant: SCHERING CORP
Inventor: ASBEROM THEODROS , CHACKALAMANNIL SAMUEL , CLASBY MARTIN C , CZARNIECZKI MICHAEL F , DOLLER DARIO , XIA YAN
IPC: C07D491/056 , A61K31/4184 , A61K31/423 , A61K31/427 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/4738 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P35/00 , A61P43/00 , C07D401/06 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/06 , C07D417/06 , C07D417/14 , C07D471/04 , C07D491/04 , C07D493/04 , C07D493/10
Abstract: Heterocyclic-substituted tricyclics of formula (I) or a pharmaceutically acceptable salt thereof, wherein: the single dotted line represents an optional double bond; the double dotted line represents an optional single bond; n is 0-2; Q is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group; B is -(CH2)n3-, wherein n3 is 0-5, -CH2-O-, -CH2S-, -CH2-NR -, -C(O)NR -. -NR C(O)-, (a), optionally substituted alkenyl or optionally substituted alkynyl; X is -O- or -NR - when the double dotted line represents a single bond, or X is -OH or -NHR when the bond is absent; Y is =O, =S, (H, H), (H, OH) or (H, C1-C6 alkoxy) when the double dotted line represents a single bond, or when the bond is absent, Y is =O, (H, H), (H, OH), (H, SH) or (H, C1-C6 alkoxy); R is absent when the double dotted line represents a single bond and is H, -NR R , or -OR when the bond is absent; or Y is (A) or (B) and R is H or C1-C6 alkyl; are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.
-
公开(公告)号:NZ504218A
公开(公告)日:2002-04-26
申请号:NZ50421898
申请日:1998-11-23
Applicant: SCHERING CORP
Inventor: CHACKALAMANNIL SAMUEL , ASBEROM THEODROS , XIA YAN , DOLLER DARIO , CZARNIECKI MICHAEL F , CLASBY MARTIN C
IPC: C07D491/056 , A61K31/4184 , A61K31/423 , A61K31/427 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/4738 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P35/00 , A61P43/00 , C07D401/06 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/06 , C07D417/06 , C07D417/14 , C07D471/04 , C07D491/04 , C07D493/04 , C07D493/10
Abstract: A compound of formula (I) wherein: the single dotted line represents an optional double bond; the double dotted line represents an optional single bond; n is 0-2; Q is a group of formula (II) wherein n1 and n2 are independently 0-2; or when the double bond is not present, Q is also fused R-substituted aryl or R-substituted heteroaryl; R is 1 to 3 substituents independently selected from the group consisting of H, alkyl, halogen, hydroxy, amino, alkylamino, dialkylamino, alkoxy,-COR16,-COOR17,-SOR16, -SO2R16,-NR16COR16a, -NR16COOR16a,-NR16CONR4R5, fluoralkyl, difluoro alkyl, trifluoroalkyl, cycloalkyl, alkenyl, arylalkyl, arylalkenyl, heteroarylalkyl, heteroarylalkenyl, hydroxyalkyl, aminoalkyl, aryl and thioalkyl; R1 and R2 are independently selected from the group consisting of H, alkyl, fluoroalkyl, difluoroalkyl, trifluoroalkyl, cycloalkyl, alkenyl, arylalkyl, arylalkenyl, heteroarylalkyl, heteroarylalkenyl, hydroxyalkyl, aminoalkyl, aryl and thioalkyl; or R1 and R2 together form a =O group; R3 is H, hydroxy, alkoxy, -SOR16, -SO2R17, -C(O)OR17, -C(O)NR13R19, alkyl, halogen, fluoroalkyl, difluoroalkyl, trifluoroalkyl, cycloalkyl, alkenyl, arylalkyl, arylalkenyl, heteroarylalkyl, heteroarylalkenyl, hydroxyalkyl, aminoalkyl, aryl or thioalkyl; Het is a mono-, bi-or tricyclic heteroaromatic group of 5 to 14 atoms comprise of 1 to 13 carbon atoms and 1 to 4 heteroatoms independently selected from the group consisting of N, O and S, wherein a ring nitrogen can form an N-oxide or a quaternary group with an alkyl group; wherein Het is attached to B by a carbon atom ring member, and wherein the Het group is substituted by 1 to 4 substituents W; Each W is independently selected from the group consisting of H, alkyl, fluoroalkyl, difluoroalkyl, trifluoroalkyl, cycloalkyl, heterocycloalkyl, heterocycloalkyl substituted by alkyl or alkenyl, alkenyl, R21-arylalkyl, R21-aryalkenyl, heteroarylalkyl, heteroarylalkenyl, hydroxyalkyl, dihydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, thioalkyl, alkoxy, alkenyloxy, halogen, -NR4R5,-CN,-OH,-COOR17, -COR16 ,-OSO2CF3,-CH2OCH2CF3, alkylthio,-C (O) NR4R5, -OCHR6-phenyl, -NHSO2R16,-NHCOR16, biphenyl, -OC(R6)2COOR7,-OC(R6)2C(O)NR4R5, alkoxy, alkoxy substituted by alkyl, amino,-OH, COOR17, -NHCOOR17, -CONR4R5, aryl, aryl substituted by 1 to 3 substituents independently selected from the group consisting of halogen,-CF3, alkyl, alkoxy and-CoOR17, aryl wherein adjacent carbons form a ring with a methylenedioxy group,-C(O)NR4R5 and heteroaryl; R21 is aryl, aryl wherein adjacent carbons form a ring with a methylenedioxy group, heteroaryl, heteroaryl substituted by 1 to 4 substituents selected from the group consisting of halogen, alkoxy alkyl, alkylamino, dialkylamino,-OCF3,-NO2, hydroxyalkyl,-CHO and phenyl, and heteroaryl wherein adjacent carbon atoms form a ring with an alkylene group or a methylenedioxy group; R4 and R5 are independently selected from the group consisting of H, alkyl, phenyl, benzyl and cycloalkyl, or R4 and R5 together are -(CH2)4-, -(CH2)5- and- (CH2)2NR7(CH2)2- and form a ring with the nitrogen to which they are attached; R6 is independently selected from the group consisting of H, alkyl and phenyl; R7 is H or alkyl; R8, R10 and R11 are independently selected from the group consisting of R1 and -OR1, provided that when the optional double bond is present, R10 is absent, and when ring Q is aromatic, R10 and R11 are absent; R9 is H, OH, alkoxy, halogen or haloalkyl; B is -(CH2)n3-, -CH2-O-, -CH2S-, -CH2-NR6-, -C(O)NR6-, -NR6C(O)-, -CH-(CH2)-CH-, cis or trans -(CH2)n4CR12=CR12a(CH2)- or (CH2)n4C=C(CH2)- wherein n3 is 0-5 , n4 and n5 are independently 0-2 and R12 and R12a are independently selected from the group consisting of H, alkyl and halogen; X is -O- or -NR6- when the double dotted line represents a single bond, or X is-OH or -NHR20 when the bond is absent; Y is =O, =S, (H, H), (H, OH) or (H, alkoxy) when the double dotted line represents a single bond, or when the bond is absent, Y is =O, (H, H), (H, OH), (H, SH) or (H, alkoxy); R15 is absent when the double dotted line represents a single bond and is H, alkyl, -NR13R19, or-OR17 when the bond is absent, or Y is -OCH2-CH2O- or -SCH2-CH2S- and R15 is H or alkyl; R16 and R16a are independently selected from the group consisting of lower alkyl, phenyl or benzyl; R17, R18 and R19 are independently selected from the group consisting of H, alkyl, phenyl, benzyl; R20 is H, alkyl, phenyl, benzyl, -C(O)R6 or -SO2R6; R21 is 1 to 3 substituents independently selected from the group consisting -OCF3, -CF3, alkyl, alkoxy, -NO2, alkylamino, di-alkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, -COR17, -NHCOR16, -NHSO2R16, -COOR-17, -NHSO2CH2CF3; Z is -O-, -S(O)0-2-, -NR22-, -C(O)-, -C(=NOR17)- or -CH2-, -C(R13R14)-, wherein R13 and R14, together with the carbon to which they are attached, form a spirocycloalkyl group of 3 to 6 carbons, or a spiroheterocycloalkyl group of 3 to 6 members comprised of 2 to 5 carbon atoms and 1 or 2 heteroatoms selected from the group consisting of O, S and N, and R22 is H, alkyl, phenyl, benzyl,-COR16 or-CONR18R19. The compounds are useful for inhibiting thrombin receptors and therefore in treating thrombosis, atherosclerosis, restinosis, hypertension, angina pectoris, arrhythmia, heart failure, myocardial infarction, glomerulonephritis, thrombotic stroke, thromboembolytic stroke, peripheral vascular diseases, inflammation disorders, cerebral ischemia and cancer.
-
公开(公告)号:AU728592B2
公开(公告)日:2001-01-11
申请号:AU3581097
申请日:1997-07-08
Applicant: SCHERING CORP
Inventor: ASBEROM THEODROS , LOWE DEREK B , GREEN MICHAEL J
IPC: A61K31/00 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/4465 , A61K31/4468 , A61K31/4545 , A61K45/06 , A61P25/28 , C07D211/58 , C07D405/12 , C07D405/14 , C07D409/14
Abstract: 1,4-Di-substituted piperidine muscarinic antagonists of formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein X is a bond, -O-, -S-, -SO-, -SO2-, -CO-, -C(OR )2-, -CH2-O-, -O-CH2-, -CH=CH-, -CH2-, -CH(C1-C6 alkyl)-, -C(C1-C6 alkyl)2-, -CONR -, -NR CO-, -SO2NR - or -NR SO2-; R is C3-C6 cycloalkyl, (a), (b), (c), (d), (e), optionally substituted phenyl or optionally substituted pyridyl; R is H, -CN, -CF3, alkyl, cycloalkyl, cycloalkenyl, alkenyl, -COR , -COO(alkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl), alkylaryl, alkylheteroaryl or -CON(R )2; R is cycloalkyl, cycloalkenyl, t-butoxycarbonyl or optionally substituted 4-piperidinyl; R and R are H, halo, -CF3, alkyl, alkoxy or -OH; R and R are H, alkyl, -CF3, alkoxy, -OH, alkylcarbonyl, alkoxycarbonyl, R CONH-, R OCONH-, R NHCONH- or NH2CONR -; R is H or alkyl, or the two R groups may form -(CH2)2-4; R is H, alkyl, cycloalkyl, -(alkyl)COOR , aryl, heteroaryl, alkylaryl, alkylheteroaryl and adamantyl; R is H or alkyl; R is H, C1-C20 alkyl, C1-C6 cycloalkyl, aryl or heteroaryl; and R is H, C1-C6 alkyl, aryl or heteroaryl; useful for treating cognitive disorders such as Alzheimer's disease are disclosed, as well as pharmaceutical compositions and methods of preparation. Also disclosed are combinations of compounds of formula (I) capable of enhancing ACh release with ACh'ase inhibitors.
-
公开(公告)号:NO20002659A
公开(公告)日:2000-07-24
申请号:NO20002659
申请日:2000-05-24
Applicant: SCHERING CORP
Inventor: CHACKALAMANNIL SAMUEL , ASBEROM THEODROS , XIA YAN , DOLLER DARIO , CLASBY MARTIN C , CZARNIECKI MICHAEL F
IPC: C07D491/056 , A61K31/4184 , A61K31/423 , A61K31/427 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/4738 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P35/00 , A61P43/00 , C07D401/06 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/06 , C07D417/06 , C07D417/14 , C07D471/04 , C07D491/04 , C07D493/04 , C07D493/10 , A61K31/4427
CPC classification number: C07D401/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/14 , C07D417/06 , C07D471/04 , C07D491/04 , C07D493/10
-
公开(公告)号:NO20002659D0
公开(公告)日:2000-05-24
申请号:NO20002659
申请日:2000-05-24
Applicant: SCHERING CORP
Inventor: CHACKALAMANNIL SAMUEL , ASBEROM THEODROS , XIA YAN , DOLLER DARIO , CLASBY MARTIN C , CZARNIECKI MICHAEL F
IPC: C07D491/056 , A61K31/4184 , A61K31/423 , A61K31/427 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/4738 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P35/00 , A61P43/00 , C07D401/06 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/06 , C07D417/06 , C07D417/14 , C07D471/04 , C07D491/04 , C07D493/04 , C07D493/10 , C07D
Abstract: Heterocyclic-substituted tricyclics of formula (I) or a pharmaceutically acceptable salt thereof, wherein: the single dotted line represents an optional double bond; the double dotted line represents an optional single bond; n is 0-2; Q is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group; B is -(CH2)n3-, wherein n3 is 0-5, -CH2-O-, -CH2S-, -CH2-NR -, -C(O)NR -. -NR C(O)-, (a), optionally substituted alkenyl or optionally substituted alkynyl; X is -O- or -NR - when the double dotted line represents a single bond, or X is -OH or -NHR when the bond is absent; Y is =O, =S, (H, H), (H, OH) or (H, C1-C6 alkoxy) when the double dotted line represents a single bond, or when the bond is absent, Y is =O, (H, H), (H, OH), (H, SH) or (H, C1-C6 alkoxy); R is absent when the double dotted line represents a single bond and is H, -NR R , or -OR when the bond is absent; or Y is (A) or (B) and R is H or C1-C6 alkyl; are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.
-
公开(公告)号:PL331534A1
公开(公告)日:1999-07-19
申请号:PL33153497
申请日:1997-08-06
Applicant: SCHERING CORP
Inventor: LOWE DEREK B , CHANG WEI K , KOZLOWSKI JOSEPH A , BERGER JOEL G , MCQUADE ROBERT , BARNETT ALLEN , SHERLOCK MARGARET , TOM WING , DUGAR SUNDEEP , CHEN LIAN-YONG , CLADER JOHN W , CHACKALAMANNIL SAMUEL , WANG YUGUANG , MCCOMBIE STUART W , TAGAT JAYARAM R , VICE SUSAN F , VACCARO WAYNE D , GREEN MICHAEL J , BROWNE MARGARET E , ASBEROM THEODROS , BOYLE CRAIG D , JOSIEN HUBERT B
IPC: A61K31/00 , A61K31/435 , A61K31/4427 , A61K31/443 , A61K31/4433 , C07D211/58 , A61K31/445 , A61K31/4465 , A61K31/4523 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/496 , A61K31/50 , A61K31/501 , A61K45/00 , A61P25/28 , C07D211/24 , C07D211/32 , C07D211/96 , C07D239/34 , C07D257/04 , C07D295/02 , C07D295/03 , C07D295/084 , C07D295/088 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/145 , C07D295/15 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14
Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) wherein R, R1, R2, R3, R4, R21, R27, R28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula with acetylcholinesterase inhibitors.
-
公开(公告)号:CZ9900366A3
公开(公告)日:1999-06-16
申请号:CZ36699
申请日:1997-08-06
Applicant: SCHERING CORP
Inventor: LOWE DEREK B , CHANG WEI K , KOZLOWSKI JOSEPH A , BERGER JOEL G , MCQUADE ROBERT , BARNETT ALLEN , SHERLOCK MARGARET , TOM WING , DUGAR SUNDEEP , CHEN LIAN-YONG , CLADER JOHN W , CHACKALAMANNIL SAMUEL , WANG YUGUANG , MCCOMBIE STUART W , TAGAT JAYARAM R , VICE SUSAN F , VACCARO WAYNE D , GREEN MICHAEL J , BROWNE MARGARET E , ASBEROM THEODROS , BOYLE CRAIG D , JOSIEN HUBERT B
IPC: C07D211/58 , A61K31/00 , A61K31/435 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/4465 , A61K31/4523 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/496 , A61K31/50 , A61K31/501 , A61K45/00 , A61P25/28 , C07D211/24 , C07D211/32 , C07D211/96 , C07D239/34 , C07D257/04 , C07D295/02 , C07D295/03 , C07D295/084 , C07D295/088 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/145 , C07D295/15 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
CPC classification number: C07D405/14 , C07C2601/14 , C07D211/24 , C07D211/32 , C07D239/34 , C07D257/04 , C07D295/03 , C07D295/088 , C07D295/092 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/145 , C07D295/15 , C07D405/12 , C07D409/14
-
公开(公告)号:AU3581097A
公开(公告)日:1998-02-02
申请号:AU3581097
申请日:1997-07-08
Applicant: SCHERING CORP
Inventor: ASBEROM THEODROS , LOWE DEREK B , GREEN MICHAEL J
IPC: A61K31/00 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/4465 , A61K31/4468 , A61K31/4545 , A61K45/06 , A61P25/28 , C07D211/58 , C07D405/12 , C07D405/14 , C07D409/14
Abstract: 1,4-Di-substituted piperidine muscarinic antagonists of formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein X is a bond, -O-, -S-, -SO-, -SO2-, -CO-, -C(OR )2-, -CH2-O-, -O-CH2-, -CH=CH-, -CH2-, -CH(C1-C6 alkyl)-, -C(C1-C6 alkyl)2-, -CONR -, -NR CO-, -SO2NR - or -NR SO2-; R is C3-C6 cycloalkyl, (a), (b), (c), (d), (e), optionally substituted phenyl or optionally substituted pyridyl; R is H, -CN, -CF3, alkyl, cycloalkyl, cycloalkenyl, alkenyl, -COR , -COO(alkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl), alkylaryl, alkylheteroaryl or -CON(R )2; R is cycloalkyl, cycloalkenyl, t-butoxycarbonyl or optionally substituted 4-piperidinyl; R and R are H, halo, -CF3, alkyl, alkoxy or -OH; R and R are H, alkyl, -CF3, alkoxy, -OH, alkylcarbonyl, alkoxycarbonyl, R CONH-, R OCONH-, R NHCONH- or NH2CONR -; R is H or alkyl, or the two R groups may form -(CH2)2-4; R is H, alkyl, cycloalkyl, -(alkyl)COOR , aryl, heteroaryl, alkylaryl, alkylheteroaryl and adamantyl; R is H or alkyl; R is H, C1-C20 alkyl, C1-C6 cycloalkyl, aryl or heteroaryl; and R is H, C1-C6 alkyl, aryl or heteroaryl; useful for treating cognitive disorders such as Alzheimer's disease are disclosed, as well as pharmaceutical compositions and methods of preparation. Also disclosed are combinations of compounds of formula (I) capable of enhancing ACh release with ACh'ase inhibitors.
-
-
-
-
-
-
-
-
-